Clinical Trial

Locally Advanced or Metastatic Tumors Treatments

Study Description

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - RO7198457

RO7198457 will be administered by intravenous (IV) infusion, in 21-day cycles.

Drug - Atezolizumab

Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.

Additional Information

Official Study Title

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

Clinical Trial ID

NCT03289962

ParticipAid ID

7axMJb